Novartis wins FDA approval for Tasigna

Novartis has won FDA approval of Tasigna for patients with chronic myeloid leukemia who are resistant to Gleevec. Patients will be tested for the Philadelphia chromosome. "Tasigna represents an important advance for the small number of patients who are resistant or intolerant to prior therapy," said David Epstein, president and chief executive of Novartis Oncology. "This approval means we can offer physicians a comprehensive treatment approach with effective medicines to treat their Ph+ CML patients."

- see this release from Novartis
- read the report from MarketWatch on the approval

ALSO: Novartis was sued by a U.S. law firm claiming the drug giant withheld adverse research information on Tasigna. Report

Related Articles:
Novartis makes the "Biggest Splash." Report
Lagging sales spur Novartis layoffs. Report
Novartis plots $700M biotech plant. Report
Novartis bankrolls a drug manufacturing revolution. Report

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.